Previously reported series in lung cancer have identified discordant molecular evolution of classical EGFR mutations (eg, EGFR T790M, wild-type EGFR, and MET alterations) during the process of metastasis and among cases with MRs,10,17 but such genomic considerations seem unlikely to apply to the present study’s population of EGFR wild-type NSCLC treated with cytotoxic and antiangiogenic agents. The gene discussed is MET; the disease is non-small cell lung carcinoma.